Immune Network Ltd (fka IMMFF)

[lifegear]

I found it...85% acquisition

Immune Network to Tackle Diabetes
Market Wire, January, 2006
Immune Network Ltd. (OTC: IMMFF) advises that it has acquired an 85% interest in B.C.-based Dr Nature Health Products Inc. -- which has a breakthrough natural health product, DRN 11, that is proven clinically beneficial in the management of diabetes -- in exchange for 7.5 million Immune Network shares.

Immune will now commence marketing DRN 11, the flagship product developed by Dr Nature over the past eight years. Completed regulatory filing for DRN 11 in Canada allows the Company to commence sales immediately. Sales into the U.S. and other markets will also be pursued.

Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's response to its own insulin making it work more efficiently (by increasing insulin binding and internalization). As a result of better utilization of insulin, muscle cell glucose uptake is increased. The significant clinical benefits against all diabetes symptoms and complications have been demonstrated through three DRN 11 clinical studies.

DRN 11 is an excellent supplement compound that can be used alongside prescription medications such as the US$800 million drug Metformin. In the DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar levels have complemented a noted quality of life benefit with no side effects and an overall improvement in the well being and general health of the study participants.

Diabetes is the third leading cause of death in the United States with an economic cost of over $100 billion per year and affecting 18.2 million people with an estimated 15 million not yet diagnosed.

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

For further information contact: Dr. Allen Bain 1-650-241-1888 Email Contact